The Hindu Business Line : Ranbaxy launches drug for erectile dysfunction

RANBAXY Laboratories Ltd has launched Forzest (Tadalafil), its most recently approved prescription medicine for the treatment of erectile dysfunction (ED) in men.

Currently, oral specific medication for management of erectile dysfunction, Sildenafil, is available. This is valued at Rs 70 crore. However, in the case of Sildenafil, the pill has to be taken one hour before the indulgence. But Forzest has an advantage over Sildenafil in terms of longer therapeutic window as it acts faster and more importantly can be taken any time up to 36 hours in advance. Given these advantages, Tadalafil gives "freedom of choice" and has been called as the weekend pill.

Erectile dysfunction is a seriously under-diagnosed condition, which largely goes untreated due to embarrassment of patients. It is estimated that about 150 million people suffer from it and about nine out of every 10 men do not seek treatment.

In India, it is estimated that about 50 million patients suffer from the disorder. Studies also indicate that men with diabetes have three-fold higher incidence and 50 per cent of them develop the condition within 10 years of being diagnosed with diabetes.

Mr Sanjeev I. Dani, Regional Director, India operations, Ranbaxy, said, "Introduction of Forzest will provide Indian doctors with best-in-class and contemporary therapeutic option for management of erectile dysfunction, which also gives greater time window to the patients".

More Stories on : Announcements | New Products & Services | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page